

Secondary minimal change disease

Richard J. Glassock

The Geffen School of Medicine at UCLA, California, USA

Abstract

The great majority of patients identified as having a 'minimal change lesion' accompanying the nephrotic syndrome have a primary or 'idiopathic' disorder. Nevertheless, it is quite apparent that a similar or identical lesion can appear consequent to a growing number of underlying diseases; it is then known as 'secondary minimal change disease'. The predisposing conditions include neoplastic diseases, toxic or allergic reactions to drugs, infections, auto-immune disorders and other miscellaneous entities. These disorders are reviewed and catalogued in this contribution.

Keywords: drugs; infections; minimal change; minimal change disease; neoplasia; nephropathy; secondary nephrotic syndrome

Introduction

The term minimal change disease (MCD) is representative of 'hybrid' nomenclature in that it describes a morphological finding, which also connotes a clinical phenotype [1]. Although the pathogenesis of this disorder remains obscure, it is very likely that a systemic disturbance is responsible for the characteristic 'leakiness' of the glomerular capillaries and the diffuse effacement of epithelial cell foot processes. Delineation of primary and secondary forms of MCD may provide an artificial separation of disorders, which have a common underlying pathogenetic basis. Primary or 'idiopathic' MCD is characterized by perturbations in glomerular permselectivity (chiefly charge selective) and typical, but not pathognomonic, morphological changes in glomerular capillaries in the absence of any identifiable extraglomerular disease process, other than that engendered by the biochemical disturbances which result from proteinuria itself [1]. On the other hand, secondary MCD is defined by the presence of some

identifiable extraglomerular disease process occurring concomitantly with the morphologic and functional abnormalities of MCD, irrespective of underlying pathogenetic mechanism. Viewed in this context, secondary MCD takes on several forms.

- (i) Secondary MCD wherein the extraglomerular disease process evokes, directly or indirectly, the characteristic changes in permselectivity and morphology. In this circumstance the morphology is similar, if not identical, to primary or 'idiopathic' MCD. Moreover, it is possible, even likely, that similar or identical pathogenetic mechanisms are operative. In this scenario, a distinct etiologic link is presumed to exist between the extraglomerular disease process and the occurrence of MCD. Such a linkage would be strongly supported if cure of the extraglomerular disease lead to the eradication of MCD and if recurrence of the extraglomerular disorder was associated with relapse.
- (ii) Primary MCD or its treatment creates an environment which fosters the emergence of the sporadic but spontaneous generation of extraglomerular disease.
- (iii) The underlying genetic determinants of susceptibility to MCD also increase susceptibility to a pathogenetically unrelated and distinct extraglomerular disease process.
- (iv) The association of MCD and an extraglomerular disease process is purely coincidental.

Of course, the first scenario listed above is most interesting as it affords an opportunity to explore mechanisms common to the primary and secondary forms of disease. The final scenario is difficult to evaluate as the critical appraisal of differences between chance and causal association requires extensive epidemiological information, which is often lacking for uncommon lesions. Thus, reports of an association between MCD and an extraglomerular disease process, which are based on single cases represent anecdotes, even though it would be quite uncommon for two rather rare disease processes to occur together simultaneously.

Correspondence and offprint requests to: Richard J. Glassock, MD, 8 Bethany, Laguna Niguel, CA 92677, USA. Email: glassock@cox.net

The purpose of this presentation will be to catalogue the known secondary forms of MCD in an attempt to characterize them with respect to the nature of the relationship between the extraglomerular disease process and the functional morphologic changes in the glomeruli characteristic of MCD. This subject has also been recently reviewed by Glasscock, Adler and Cohen [1].

Characterization of secondary minimal change disease

The six main categories of secondary MCD are listed in Table 1 [1]. While an attempt has been made to be comprehensive, it is possible that individual reports describing an association between the specific extraglomerular disease and MCD may have been overlooked. The majority of the instances in which MCD has been associated with an extraglomerular disease involve neoplastic processes and idiosyncratic, hypersensitivity or toxic reactions to drugs.

Neoplasia

A variety of neoplastic processes have been reported in association with MCD (Table 2) [2–45]. In some, the association is rare enough to suspect that chance alone may have been the operational mechanism underlying the association. In others, the association is clearly contemporaneous and likely causal. Among patients with glomerular disease associated with neoplasia, ~40% have MCD on renal biopsy. As mentioned previously it is possible that some of the described associations between neoplasia and MCD may be the consequence of treatment of MCD (especially cytotoxic drug therapy) predisposing to the emergence of a malignancy.

Hodgkin's disease and non-Hodgkin's lymphoma are among the most frequently reported neoplastic processes associated with MCD [4–19]. Interestingly, reports describing the concurrence of MCD and Hodgkin's disease have decreased in recent years, perhaps due to the more effective diagnostic and therapeutic strategies available for this and related diseases. MCD is a rare complication of Hodgkin's disease occurring in from 1:2000 to 1:10 000 cases.

Table 1. Categorization of secondary MCD (76^a)

- Neoplasia (19)
- Drugs (24)
- Infections (7)
- Atopy (6)
- Superimposed on another renal disease (5)
- Miscellaneous (15)

^aThe number in parentheses indicates the number of specific diseases or clinico-pathologic entities reported to be associated with MCD.

MCD has been associated with both limited (Stage 1) and disseminated (Stage 4) forms of Hodgkin's disease. Therapy of Hodgkin's disease, either by local radiotherapy to regional lymph nodes or by systemic chemotherapy, has often resulted in remission of MCD and recurrences of Hodgkin's disease have been associated with recurrence of MCD [6,7,16,19]. These observations strongly imply a causal relationship between the tumour (or a product of the abnormal neoplastic cells) and the pathophysiological abnormalities involved in MCD. Indeed, it is quite possible that the same clone of cells which are involved in the development of Hodgkin's disease are also involved in the pathogenesis of MCD in both the primary and secondary forms. Such an explanation is more difficult to conjecture for the association of MCD with the other tumours listed in Table 2, except for mycosis fungoides, angiofollicular lymph node hyperplasia, non-Hodgkin's lymphoma and chronic lymphatic leukaemia [9,20,21]. Perhaps, in these instances, the perturbations for MCD have also triggered the oncogenic potential of cells predisposed to neoplastic transformation (e.g. lack of a wild type tumour suppressor gene). Alternatively, lymphocytes infiltrating neoplastic growths could be induced to elaborate factors responsible for abnormal permeability. Whatever the case may be, it is worthwhile to consider potential underlying neoplasia in patients with MCD when atypical features are present such as weight loss, anorexia, lymphadenopathy, haematuria, fever, pleural effusions or skin lesions. Overall, the occurrence of MCD as a complication of neoplastic disorders is quite uncommon. MCD may precede the diagnosis of neoplasia by months or years or may follow the diagnosis of neoplasia by months or years. Some reports have suggested that NK-cell deficiency is associated with the development of MCD in patients with Hodgkin's disease [14].

Table 2. Neoplasms associated with MCD (19^a)

- Hodgkin's disease
- Non-Hodgkin's lymphoma
- Leukaemia (chronic lymphatic, intravascular lymphoma)
- Thymoma (with or without myasthenia gravis)
- Renal cell carcinoma
- Mesothelioma
- Bronchogenic carcinoma
- Colon carcinoma
- Pancreatic carcinoma
- Urothelial cancer
- Prostatic carcinoma
- Renal oncocytoma
- Angiofollicular lymph node hyperplasia
- Mycosis fungoides
- Neurilemmoma
- Waldenstrom's macroglobulinemia
- Chordoma
- Lymphoid hamartoma
- Kimura's disease

^aSee references [2–45]; the number in parentheses indicates the number of different diseases associated with MCD.

Drugs

MCD is increasingly recognized as a complication of therapy with a variety of agents [46–63]. These are listed in Table 3. In many cases, a hypersensitivity reaction rather than a direct toxic effect appears to be involved. Nevertheless, it is possible that some of the agents listed in Table 3 may exert their harmful effects on glomerular capillaries through a direct toxic effect (e.g. daunomycin, lithium and interferon). Agents in the non-steroidal anti-inflammatory drug classification can produce heavy proteinuria and nephrotic syndrome associated with glomerular lesions identical to that seen in primary MCD. In most, but not all, cases there is a concomitant acute interstitial nephritis characterized by the influx of polyclonal T and B cells [46–51]. Clinically, the association of NSAID with MCD is also characterized by an abrupt decline in renal function, usually eventuating in acute renal failure. Skin rashes and fever are uncommon.

Recrudescence may occur upon re-exposure to the drug, implying that a cell-mediated hypersensitivity reaction is operative. Withdrawal of the agent is usually associated with full recovery but glucocorticoids may hasten the rate of return of renal function and disappearance of proteinuria. Nevertheless, a clear beneficial effect of steroids on the course of NSAID induced MCD is not yet established. Systemic release of permeability promoting factors from activated inflammatory or immune cells may be the basis for the association between drug exposure and MCD. As mentioned above, some compounds may have direct toxic effects on the integrity of the glomerular epithelial cell thus resulting in abnormal glomerular permeability and the effacement of foot processes so characteristic of MCD. It is likely, though not yet proven, that genetic susceptibility to the toxic effects of drugs or to the release of endogenous permeability promoting products plays a role in the association of MCD with drug exposure. Although an accompanying interstitial inflammation is frequently a harbinger of a drug-associated secondary MCD, a few reports have indicated that drugs may result in the lesion of MCD

Table 3. Drugs associated with MCD (24^a)

-
- Gold
 - Antimicrobials (ampicillin, rifampicin, cefixime)
 - NSAIDs (ibuprofen, fenoprofen, piroxicam, diclofenac, tolmetin, naproxen, zomepirac, indomethacin)
 - Trimethadione
 - Paramethadione
 - Lithium
 - Interferon (α , γ)
 - Methimazole
 - Tamoxifen
 - Enalapril
 - Penicillamine
 - Probenecid
 - Immunizations
-

^aSee references [46–63]; the number in parentheses indicates the number of specific drugs associated with MCD.

without any accompanying interstitial inflammation [46–51]. Thus, a thorough drug history should be obtained in all patients presenting with nephrotic syndrome due to MCD and, if possible, potentially offending drugs should be discontinued before ascribing the lesion to the ‘idiopathic’ category.

Infections

Although MCD and nephrotic syndrome represents a clinical state of enhanced susceptibility to infection, the causal relationship between an infectious disease and the development of MCD has been suspected only rarely [64–74]. The infectious diseases in which MCD is thought to have occurred on a secondary basis (rather than vice versa) are shown in Table 4. The precise relationship between the infectious disease and MCD in these circumstances is unknown. It is possible that these infectious agents activate a subset of lymphocytes capable of elaborating permeability factors. Often, with appropriate anti-microbial therapy of the underlying infectious disease, the MCD will abate.

Atopy

A heightened allergic reactivity to environmental agents has long been associated with MCD [75–81]. Indeed, many authors have described the onset of MCD or its relapse as being clearly related to an allergic reaction (such as bee sting or other envenomations).

It is possible that the phenomenon of IgE-ediated hypersensitivity is pathogenetically related to the development of MCD, although IgE deposition is not noted in the renal lesions. IgE levels are elevated in ~50% of patients with MCD. Table 5 lists the more common associations of atopy with MCD (including

Table 4. Infections associated with MCD (7^a)

-
- Syphilis
 - Tuberculosis (?)
 - Human Immunodeficiency Virus
 - Mycoplasma
 - Ehrlichiosis
 - Echinococcus (hydatid disease)
 - Schistosomiasis
-

^aSee references [68–74]; the number in parentheses indicates the number of specific infections associated with MCD.

Table 5. Atopic agents associated with MCD (6^a)

-
- Pollen
 - Dairy products (milk)
 - House dust
 - Pork
 - Bee stings
 - Poison oak/ivy
-

^aSee references [75–81]; the number in parentheses indicates the number of atopic diseases or circumstances associated with MCD.

eczema, hives, contact dermatitis, hay fever and rhinitis). The avoidance of potential allergens, such as dairy products, pork, house dust and pollen can occasionally be associated with prolonged remissions of MCD. Some reports have described that seasonal recurrences of MCD can be linked to an allergic disorder [80]. Unfortunately, treatment of individuals displaying a background of atopy accompanying MCD with cromoglycate has been quite unsuccessful. Some reports have described an underlying genetic susceptibility to both the allergic disorder and MCD (e.g. HLA-B12), and thus it is possible that the association of atopy and MCD is more fortuitous than direct.

Associated with other glomerular or renal diseases

MCD and nephrotic syndrome may be observed in association with other renal disease [82–88]. These are listed in Table 6. These associations probably occur in excess of that expected by chance alone and may be due to some common genetically based susceptibility. Extensive mesangial IgA deposition may be seen in some instances of MCD [86]. These patients behave more like MCD than IgA nephropathy in that they are responsive to glucocorticoids and have a benign prognosis. New onset type 1 insulin-dependent diabetes mellitus is associated with the development of nephrotic syndrome due to MCD in rare circumstances [85]. This lesion appears to be responsive to glucocorticoids. Whether the diabetic state, *per se*, induces abnormalities, which result in the lesion of MCD or whether the concurrence of these two lesions is the result of some common genetic susceptibility remains uncertain [84]. Based on current observations, the latter possibility appears more likely. With an incidence of 1:300 for type 1 diabetes and 1:50 000 for MCD, the two disorders would be expected to occur together by chance alone in 1:15 000 000 individuals. Very rarely MCD may be a part of the presentation of systemic lupus erythematosus or occur as a complication of autosomal dominant or recessive polycystic kidney disease. In both circumstances, the lesion appears to be responsive to glucocorticoids and may merely be the superimposition of ‘primary’ MCD on the systemic disease [82,83].

Miscellaneous

A large number of reports (usually single case reports) have appeared describing the association of MCD with another disease process [89–105]. These vary widely

Table 6. MCD superimposed on another renal disease (5^a)

- IgA nephropathy
- Systemic lupus erythematosus
- Diabetes mellitus (new onset type 1)
- Autosomal dominant and recessive polycystic kidney disease
- HIV associated nephropathy

^aSee references [82–88]; the number in parentheses indicates the number of specific diseases associated with MCD.

from acute decompression illness to vigorous exercise. The exact relationship between the concurrence of the extraglomerular disease and MCD remains unknown, and many of these instances may present chance rather than causal associations. A list of the miscellaneous disorders associated with MCD is presented in Table 7.

Discussion

The extraglomerular disease processes, which have been associated with MCD are both numerous and diverse. It is difficult to discern a common theme in the spectrum of disease associations. Nevertheless, the associations between MCD and neoplasia and drugs strongly suggest that some perturbation of cellular immunity is involved. It is possible that the extraglomerular disease stimulates a subset of lymphocytes to elaborate permeability factors identical to that responsible for the primary lesion. Alternatively, deficiency states, such as natural killer cell deficiency, may give rise to perturbations in the immune system favouring the elaboration of permeability factors. Direct demonstration of some commonality in pathogenesis between primary and secondary forms of MCD must await the identification and characterization of putative permeability factors and the definition of the cellular origin of these permeability promoting substances. From a clinical perspective, it is important to keep in mind that, in some instances, apparently ‘idiopathic’ MCD may in fact represent a lesion arising secondary to an extraglomerular disease process. In many instances, the association between the extraglomerular disease process and MCD is quite obvious; on the other hand, the clinical manifestations of the underlying extraglomerular disease process can be quite subtle. Thus, patients should be thoroughly evaluated for potential underlying diseases, particularly neoplasia and drug exposure, when atypical features are present (such as weight loss, anorexia, lymphadenopathy or acute renal failure). When interstitial inflammation is found in association with nephrotic syndrome and MCD, drug exposure,

Table 7. Miscellaneous diseases associated with MCD (15^a)

- Sclerosing cholangitis
- Sclerosing mesenteric inflammation
- Vigorous exercise
- Acute decompression sickness
- Sarcoidosis
- Grave’s disease
- Thyroiditis
- Vasculitis
- Partial lipodystrophy
- Myasthenia gravis (without apparent thymoma)
- Renal artery stenosis
- Bis-albuminaemia
- Guillain–Barre syndrome
- Dermatitis herpetiformis
- Melorheostosis, mesenteric fibrosis, haemangiomas

^aSee references [89–105]; the number in parentheses indicates the number of specific miscellaneous diseases associated with MCD.

particularly to non-steroidal anti-inflammatory agents, should be strongly suspected. Discontinuance of the drug or successful treatment of the underlying disease process (such as chemotherapy for neoplasia or antimicrobial therapy of infections) often results in a remission of MCD and a nephrotic syndrome.

The prognosis for secondary MCD is generally favourable, although extensively influenced by the nature of the extraglomerular disease process. For example, Hodgkin's disease associated with MCD that is refractory to chemotherapy would carry a very adverse prognosis. MCD associated with other renal diseases (such as IgA nephropathy, insulin-dependent diabetes mellitus, systemic lupus erythematosus or polycystic kidney disease) generally has a favourable prognosis similar to that observed with a primary MCD.

References

- Glasscock RJ, Adler S, Cohen AH. Primary glomerular diseases. In: Brenner B, ed. *The Kidney*, 5th Edn. W. B. Saunders, Philadelphia: 1996: 1435–1444
- Gagliano RG, Costanzi JJ, Beathard GA *et al.* The nephrotic syndrome associated with neoplasia: an unusual paraneoplastic syndrome. Report of a case and review of the literature. *Am J Med* 1976; 60: 1026–1031
- Eagen JW, Lewis EJ. Glomerulopathies of neoplasia. *Kidney Int* 1977; 11: 297–309
- Cotran R, Alpers CE. Neoplasia and glomerular injury. *Kidney Int* 1986; 30: 465–476
- Cornig HJ. Une forme nouvelle de la maladie de Hodgkin. Lymphogranulomatose maligne a type de nephrose lipidique. Thesis #547. Faculty de Medicine de Paris; 1939
- Sherman RL, Susin M, Weksler Becker EL. Lipoid nephrosis in Hodgkin's disease. *Am J Med* 1972; 52: 699–706
- Couser WG, Badter A, Cooperhand S *et al.* Hodgkin's disease and lipoid nephrosis. *Lancet* 1977; 1: 912–913
- Peces R, Sanchez I, Gorostidi M, Alvarez J. Minimal change nephrotic syndrome associated with Hodgkin's lymphoma. *Nephrol Dial Transplant* 1991; 6: 155–158
- Dabbs DJ, Morel-Maroger Striker L, Mignon F, Striker G. Glomerular lesions in lymphomas and leukemias. *Am J Med* 1986; 80: 63–70
- Cale WF, Ullrich IH, Jenkins JJ. Nodular sclerosing Hodgkin's disease presenting as nephrotic syndrome. *South Med J* 1982; 75: 604–607
- Plager J, Stutzman L. Acute nephrotic syndrome as a manifestation of active Hodgkin's disease. *Am J Med* 1971; 50: 56–66
- Powderly WG, Cantwell BM, Fennelly JJ *et al.* Renal glomerulopathies associated with Hodgkin's disease. *Cancer* 1985; 56: 874–875
- Moorthy AV, Zimmerman SW, Burkholder PM. Nephrotic syndrome in Hodgkin's disease: evidence for pathogenesis alternative to immune complex deposition. *Am J Med* 1976; 61: 471–477
- Mori T, Yabuhara A, Nakayama J *et al.* Frequently relapsing minimal change nephrotic syndrome with natural killer cell deficiency prior to the overt relapse of Hodgkin's disease. *Pediatr Nephrol* 1995; 9: 619–620
- Cavalli F. Rare syndromes in Hodgkin's disease. *Ann Oncol* 1998; 9: S109–S113
- Huisman RM, de Jong PE, de Zeeuw D *et al.* Nephrotic syndrome preceding Hodgkin's disease by 42 months. *Clin Nephrol* 1986; 26: 311–313
- Shapiro CM, VanderLaan BF, Jao W, Sloan DE. Nephrotic syndrome in two patients with cured Hodgkin's disease. *Cancer* 1985; 55: 1799–1804
- Berthoux FC, Zech PY, Blanc-Brunat N *et al.* Association of nephrotic syndrome and Hodgkin's disease. Role of Epstein-Barr virus. *Nouv Presse Med* 1976; 5: 255–258
- Shitara T, Sullivan MP, Brewer ED *et al.* Hodgkin's disease complicated by nephrotic syndrome. New clinical observations on the response of both diseases to radiotherapy to the neck. *Am J Pediatr Hematol Oncol* 1981; 3: 177–181
- Cronin C, Carmody E, Ryan F, Carmody M. Acute renal failure and non-Hodgkin's lymphoma in a patient with minimal change glomerulonephritis. *J Intern Med* 1990; 228: 65–68
- Rault R, Holley JL, Banner BF, el-Shahawy M. Glomerulonephritis and non-Hodgkin's lymphoma: a report of two cases and a review of the literature. *Am J Kidney Dis* 1992; 20: 84–89
- Hory B, Saunier F, Wolff R *et al.* Waldenstrom's macroglobulinemia and nephrotic syndrome with minimal change lesion. *Nephron* 1987; 45: 68–70
- D'Agati V, Sablay LB, Knowles DM, Walter L. Angiotropic large cell lymphoma (intravascular malignant lymphomatosis) of the kidney: presentation as minimal change disease. *Hum Pathol* 1989; 20: 263–268
- Straszewski H, Kumar G, Mishriki Y. Minimal change disease as the etiology of the nephrotic syndrome in a patient with angio-immunoblastic lymphadenopathy. *Med Pediatr Oncol* 1988; 16: 206–209
- Orman SV, Schechter GP, Whang-Peng J *et al.* Nephrotic syndrome associated with a clonal T-cell leukemia of large granular lymphocytes with cytotoxic function. *Arch Int Med* 1986; 146: 1827–1829
- Budak-Alpdogan T, Alpdogan O, Okar I, Akoglu E. Nephrotic syndrome associated with chronic lymphocytic leukemia. *Nephrol Dial Transplant* 1988; 13: 2418–2419
- Seney FD, Federgreen WR, Stein H, Kashrarian M. A review of nephrotic syndrome associated with chronic lymphocytic leukemia. *Arch Int Med* 1986; 146: 137–141
- Thomson M, de Arriba G, Ordi J *et al.* Acute myelogenous leukemia treated with daunomycin associated with the nephrotic syndrome. *Nephron* 1989; 51: 261–264
- Hirokawa M, Moriya T, Manabe T. Minimal change renal disease associated with thymoma and pancreatic carcinoma. *Acta Pathol Jpn* 1986; 36: 1075–1081
- Varsano S, Bruderman L, Bernheim JL *et al.* Minimal-change nephropathy and malignant lymphoma. *Chest* 1980; 77: 695–697
- Zinger C, Ben-Itzhak O, Szyzman P *et al.* Minimal change nephropathy and malignant thymoma. *Am J Nephrol* 1998; 18: 61–63
- Chan PC, Lau CC, Cheng IK *et al.* Minimal change nephropathy in two patients after thymectomy. *Singapore Med J* 1990; 31: 46–47
- Martinez-Vea A, Panisello JM, Garcia C *et al.* Minimal change glomerulopathy and carcinoma. *Am J Nephrol* 1993; 13: 69–72
- Singer CR, Boulton-Jones JM. Minimal change nephropathy associated with anaplastic carcinoma of the bronchus. *Postgrad Med J* 1986; 62: 213–217
- Moorthy AV. Minimal change glomerular disease: a paraneoplastic syndrome in two patients with bronchogenic carcinoma. *Am J Kidney Dis* 1983; 3: 58–62
- Gandini E, Allaria P, Castiglioni A *et al.* Minimal change nephrotic syndrome with cecum adenocarcinoma. *Clin Nephrol* 1996; 45: 268–270
- Woodrow G, Innes A, Ansell ID, Burden RP. Renal cell carcinoma presenting as nephrotic syndrome. *Nephron* 1995; 69: 166–169
- Auguet T, Lorenzo A, Colmer E *et al.* Recovery of minimal change nephrotic syndrome and acute renal failure in a patient with renal cell carcinoma. *Am J Nephrol* 1998; 18: 433–435

39. Meyrier A, Delahousse M, Callard P, Rainfray M. Minimal change nephrotic syndrome revealing solid tumors. *Nephron* 1992; 61: 220–223
40. Whelan TU, Hirszel P. Minimal-change nephropathy associated with pancreatic carcinoma. *Arch Int Med* 1988; 148: 975–976
41. Forland M, Bannayan GA. Minimal-change lesion nephrotic syndrome with renal oncocytoma. *Am J Med* 1983; 75: 715–720
42. Schroeter NJ, Rushing DA, Parker JP, Beltaos E. Minimal-change nephrotic syndrome associated with malignant mesothelioma. *Arch Int Med* 1986; 146: 1834–1836
43. Sood AK, Dua A, Mahajan A, Sharma R. Minimal change nephrotic syndrome associated with extra-renal neurilemmoma. *Nephron* 1997; 75: 230–232
44. Sud K, Saha T, Das A *et al*. Kimura's disease and minimal change nephrotic syndrome. *Nephrol Dial Transplant* 1996; 11: 1349–1351
45. Matsumoto K, Katayama H, Hatano M. Minimal change nephrotic syndrome associated with subcutaneous eosinophilic lymphoid granuloma (Kimura's disease). *Nephron* 1988; 49: 251–254
46. Feinfeld DA, Olesnick L, Pirani CL, Appel GB. Nephrotic syndrome associated with the use of the non-steroidal anti-inflammatory drugs. *Nephron* 1984; 37: 174–179
47. Brezen JH, Katz SM, Schwartz AB, Chinitz JL. Reversible renal failure and nephrotic syndrome associated with non-steroidal anti-inflammatory agents. *N Engl J Med* 1979; 301: 1271–1273
48. Kleinknecht C, Broyer M, Gubler M-C, Palcoux, JB. Irreversible renal failure after indomethacin in steroid resistant nephrosis. *N Engl J Med* 1980; 302: 691–699
49. Kleinknecht D. Interstitial nephritis, the nephrotic syndrome and chronic renal failure secondary to non-steroidal anti-inflammatory drugs. *Semin Nephrol* 1995; 15: 228–235
50. Morgenstern SJ, Bruns FJ, Fraley DS *et al*. Ibuprofen-associated lipid nephrosis without interstitial nephritis. *Am J Kidney Dis* 1989; 14: 50–52
51. Curt GA, Kaldany A, Whitley LG *et al*. Reversible rapidly progressive renal failure with nephrotic syndrome due to fenoprofen calcium. *Ann Int Med* 1980; 92: 72–73
52. Lomvardias S, Pinn VW, Wadhwa ML *et al*. Nephrotic syndrome associated with sulindac. *N Engl J Med* 1981; 304: 424–426
53. Richman AV, Masco HL, Rifkin SI, Acharya, MK. Minimal change disease and the nephrotic syndrome associated with lithium therapy. *Ann Inter Med* 1980; 92: 70–72
54. Wood IK, Parmelee DX, Foreman JW. Lithium-induced nephrotic syndrome. *Am J Psychiatry* 1989; 146: 84–87
55. Alexander F, Martin J. Nephrotic syndrome associated with lithium therapy. *Clin Nephrol* 1981; 15: 267–271
56. Baum M, Piel CF, Goodman JR. Antibiotic-associated interstitial nephritis and nephrotic syndrome. *Am J Nephrol* 1986; 6: 149–151
57. Tada T, Ohara A, Nagai Y *et al*. A case report of nephrotic syndrome associated with rifampicin therapy. *Nippon Jinzo Gakkai Shi* 1995; 37: 145–150
58. Islek I, Gok F, Albayrak D, Kucukoduk S. Nephrotic syndrome following cefixime therapy in a 10-month-old girl. Spontaneous resolution without corticosteroid treatment. *Nephrol Dial Transplant* 1999; 14: 2527
59. Falck HM, Tonroth T, Kock B, Wegelius O. Fatal renal vasculitis and minimal change glomerulonephritis complicating treatment with penicillamine. Report on two cases. *Acta Med Scand* 1979; 205: 133–138
60. Grevska L, Polenakovic M, Dsikova S, Grozdanovski R. Acute renal failure with severe tubulo-interstitial nephritis in a patient with minimal change nephrotic syndrome treated with enalapril. *Clin Nephrol* 1997; 48: 331–334
61. Lauro S, Lalle M, D'Andrea MR *et al*. Nephrotic syndrome and adjuvant treatment with tamoxifen for early breast cancer. Case report and review of the literature. *Anticancer Res*, 1994; 14: 2171–2172
62. Francis KL, Jenis EH, Jensen GE, Calcagno PL. Gold-associated nephropathy. *Arch Pathol Lab Med* 1984; 108: 234–238
63. Traynor A, Kuzel T, Samuelson E, Kanwar Y. Minimal change glomerulopathy and glomerular visceral epithelial hyperplasia associated with alpha-interferon therapy for cutaneous T-cell lymphoma. *Nephron* 1994; 67: 94–100
64. Averbuch SD, Austin HA, Sherwin SA *et al*. Acute interstitial nephritis with nephrotic syndrome following recombinant leukocyte A interferon therapy for mycosis fungoides. *N Engl J Med* 1984; 310: 32–35
65. Reynolds LR, Bhatena D. Nephrotic syndrome associated with methimazole therapy. *Arch Int Med* 1979; 139: 236–237
66. Hertz P, Yager H, Richardson JA. Probenicid-induced nephrotic syndrome. *Arch Pathol* 1972; 94: 241–243
67. Barnett HL, Simonds DJ, Wells RE Jr. Nephrotic syndrome occurring during tridione therapy. *Am J Med* 1984; 4: 760–766
68. Krane NK, Espemnan P, Walker PD *et al*. Renal disease and syphilis. A report of nephrotic syndrome with minimal change disease. *Am J Kidney Dis* 1987; 9: 176–179
69. Scaglia F, Vogler LB, Hymes LC *et al*. Minimal change disease nephrotic syndrome: a possible complication of ehrlichiosis. *Pediatr Nephrol* 1999; 13: 600–601
70. Biox E, Rivera F, Gil CM *et al*. Steroid-responsive nephrotic syndrome with minimal change disease and IgA deposits in a HIV-infected patient. *Nephrol Dial Transplant* 2000; 15: 412–414
71. Rathi AK, Kapoor AK. Tuberculosis and minimal change nephrotic syndrome in Lucknow, India. *Trop Geogr Med* 1980; 32: 227–230
72. Jones JM. Tuberculosis and minimal change nephropathy. *Scott Med J* 1984; 29: 114–116
73. Said MH, Layani MP, Colon S *et al*. *Mycoplasma pneumoniae* associated nephritis in children. *Pediatr Nephrol* 1999; 13: 39–44
74. Gelman R, Brook G, Green J *et al*. Minimal change glomerulonephritis associated with hydatid disease. *Clin Nephrol* 2000; 53: 152–155
75. Laurent J, Lagrue G, Belghiti D *et al*. Is house dust allergen a possible causal factor for relapses in lipid nephrosis? *Allergy* 1984; 39: 231–235
76. Lin CY, Lee BH, Lin CC, Chen WP. A study of the relationship between childhood nephrotic syndrome and allergic diseases. *Chest* 1990; 97: 1408–1411
77. Meadow SR, Sarsfield JK. Steroid-responsive and nephrotic syndrome and allergy: clinical studies. *Arch Dis Childh* 1981; 56: 509–516
78. Howanietz H, Lubec G. Idiopathic nephrotic syndrome treated with steroids for five years, found to be allergic to pork. *Lancet* 1985; 2: 450–452
79. Sandberg DH, McIntosh RM, Bernstein CW *et al*. Severe steroid sensitive nephrotic syndrome associated with hypersensitivity. *Lancet* 1977; 1: 388–390
80. Reeves WG, Cameron JS, Johansson SGO *et al*. Seasonal nephrotic syndrome. *Clin Allergy* 1975; 5: 121–137
81. Lagrue G, Laurent J. Allergy and lipid nephrosis. *Adv Nephrol* 1983; 12: 151–179
82. Makino H, Haramoto T, Shikata K *et al*. Minimal-change nephrotic syndrome associated with systemic lupus erythematosus. *Am J Nephrol* 1995; 15: 439–441
83. Perakis C, Arvanitis A, Sotsiou F *et al*. Nephrotic syndrome caused by minimal change disease In a patient with focal proliferative SLE nephritis (WHO III) in remission. *Nephrol Dial Transplant* 1998; 13: 467–470
84. Dornan TL, Jenkins S, Cotton RE *et al*. The nephrotic syndrome at presentation of insulin-dependent diabetes mellitus: cause or coincidence? *Diabet Med* 1988; 5: 387–390
85. Urizar RE, Schwartz A, Tpe F, Vernier RL. The nephrotic syndrome of children with diabetes of recent onset. Report of 5 cases. *N Engl J Med* 1969; 281: 173–182

86. Mustonen J, Pasternak A, Rantala I. The nephrotic syndrome in IgA nephropathy. Response to corticosteroid therapy. *Clin Nephrol* 1983; 20: 172–176
87. Banyai S, Falger J, Haag-Weber M, Horl WH. Minimal change glomerulonephritis associated with infantile autosomal recessive polycystic kidney disease. *Nephrol Dial Transplant* 1997; 12: 2726–2727
88. Nakahama H, Inoue T, Kakihara M *et al.* A case of polycystic kidney disease with nephrotic syndrome. *Urol Int* 1991; 46: 77–78
89. North-Coombes JD, Healy GF, Cochrane J. Sarcoid associated minimal change disease: a case report. *J South Carolina Med Assoc* 1998; 94: 351–353
90. Fracchia M, Manganaro M, Poccardi G *et al.* Minimal change nephropathy presenting in a patient with primary sclerosing cholangitis. *Ital J Gastroenterol Hepatol* 1997; 29: 267–269
91. Nishike M, Murakami Y, Yamane Y *et al.* Steroid sensitive nephrotic syndrome, sarcoidosis and thyroiditis—a new syndrome? *Nephrol Dial Transplant* 1999; 14: 2008–2010
92. Vernace MA, Belluci AG, Mossey RT *et al.* Minimal change nephropathy associated with sclerosing mesenteritis. *Nephron* 1996; 73: 473–476
93. Kagiya S, Tsuruta H, Tominaga M *et al.* Minimal change nephrotic syndrome and acute renal failure in a patient with aged onset insulin-dependent diabetes mellitus and autoimmune thyroiditis. *Am J Nephrol* 1999; 19: 369–372
94. Gaboardi F, Perletti L, Cambie M, Mihatsch MJ. Dermatitis herpetiformis and nephrotic syndrome. *Clin Nephrol* 1983; 20: 49–51
95. Froelish CJ, Searles RP, Davis LE, Goodwin JS. A case of Guillain-Barre syndrome with immunologic abnormalities. *Ann Int Med* 1980; 93: 563–565
96. Ritz E. Simultaneous relapse of minimal change glomerulonephritis and Grave's disease. *Nephrol Dial Transplant* 1997; 7: 1541
97. Stokke KT, Teisberg PA, Myhre E *et al.* Nephrotic syndrome in ulcerative colitis. *Scand J Gastroenterol* 1976; 11: 571–576
98. Ogawa M, Tsukahara T, Saisho H. Nephrotic syndrome with acute renal failure and cerebral infarction in a patient with myasthenia gravis. *Am J Nephrol* 1999; 19: 622–623
99. Yin PD, Chan KW, Chan MK. Minimal change nephrotic syndrome presenting after acute decompression. *Br Med J* 1986; 292: 445–446
100. Miura H, Fukul H, Hayano K *et al.* A case of minimal change nephrotic syndrome associated with acute renal failure after excessive exercise. *Nippon Jinzo Gakkai Shi* 1993; 35: 387–391
101. Jacob CK, Date A, Shastry JC. Minimal change disease with partial liposystrophy. *Child Nephrol Urol* 1988–1989; 9: 116–117
102. Roger D, Bonnetblanc JM, Leroux-Robert C. Melorheostosis with associated minimal change nephrotic syndrome, mesenteric fibromatosis and capillary hemangiomas. *Dermatology* 1994; 188: 166–168
103. Humphreys SR, Holley KE, Smith LH *et al.* Mesenteric angiofollicular lymph node hyperplasia (lymphoid hamartoma) with nephrotic syndrome. *Mayo Clin Proc* 1975; 50: 317–321
104. Eiser AR, Katz SM, Swartz C. Reversible nephrotic range proteinuria with renal arterial stenosis: a clinical example of renin associated proteinuria. *Nephron* 1982; 30: 374–382
105. Ahmad J, Khan AS, Siddiqui MA *et al.* Bisalbuminemia in nephrotic syndrome. *Jpn J Med* 1984; 23: 45–47